Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) is a prominent Canadian company headquartered in Edmonton, Alberta, dedicated to the cultivation, production, and sale of high-quality cannabis for both medical and recreational use. The company's state-of-the-art facilities in Alberta embody advanced cultivation techniques that ensure the highest standards of quality, reliability, and safety in their products. Aurora's comprehensive portfolio includes renowned brands like Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, catering to a wide range of consumer preferences.
Aurora's operations extend beyond Canada, with significant international presence through medical cannabis exporting agreements. A notable subsidiary, Australis Capital Inc., plays a crucial role in participating in the U.S. cannabis market. The company's commitment to quality is further highlighted by its EU-GMP and TGA-GMP certified production facilities, ensuring compliance with rigorous international standards.
In recent developments, Aurora has launched three new cannabis-infused beverages targeted initially at veteran patients. These products, featuring innovative SōRSE® emulsion technology, offer an alternative form of cannabis consumption without the strong cannabis aroma or taste. Available in flavors like Neon Rush, Strawberry Pineapple Tropical Fizz, and Pineapple Coconut Fizz, these beverages are designed to enhance patient wellbeing with a refreshing and potent experience.
Financially, Aurora has achieved significant milestones, including the repayment of nearly $465 million in convertible debt and forecasting positive free cash flow for calendar 2024. The company has also strengthened its global footprint by acquiring MedReleaf Australia's majority equity, further solidifying its position in the Australian market. Aurora’s commitment to financial discipline and strategic expansions underscores its potential for sustainable growth.
Aurora's dedication to innovation and patient care is exemplified through its continuous development of new products and partnerships. Their recent launches include resin cartridges and pastilles in Australia, expanding their product range and enhancing patient access to premium medical cannabis. Additionally, the company's strategic moves in Europe, particularly in Germany, position it as a leader in the evolving cannabis landscape.
With a robust pipeline of products and strategic market expansions, Aurora Cannabis Inc. continues to pave the way for significant advancements in the global cannabis industry, committed to improving lives through high-quality, innovative cannabis products.
Aurora Cannabis (NASDAQ: ACB) has expanded its medical cannabis pastille offerings in Australia, introducing three new products: 10mg THC Pomegranate Berry, 10:10 Balanced Pineapple, and 25mg CBD Acai Berry pastilles, each in 30-pack formats.
The expansion demonstrates Aurora's response to growing market demand and strengthens its position as the largest global medical cannabis company in legally operating markets. The pastilles offer several advantages, including easy oral intake, prolonged effects, and a discrete, portable format.
According to Andre Jerome, Executive VP of Global Business Development, this expansion showcases Aurora's understanding of market demand and ability to deliver high-quality products in key markets. The company plans to continue introducing new innovations through its pipeline in the coming months.
Aurora Cannabis (NASDAQ: ACB) has removed the concession card requirement for patients accessing its IndiMed medical cannabis products in Australia, expanding accessibility to all eligible patients in the market. Operating through its wholly-owned subsidiary MedReleaf Australia, this strategic move aims to create more seamless prescribing options in Australia's growing medical cannabis market.
IndiMed, launched in Australia in 2021 as the first concession product, has expanded its portfolio to include oil, dried flower products, and resin cartridges. The brand's flower products consistently rank among the top 10 most prescribed cannabis products for patients. MedReleaf Australia maintains TGA-GMP standards for quality and consistency.
The company has also filed a final short form base shelf prospectus with Canadian provincial securities regulators (except Quebec) and a corresponding shelf registration statement on Form F-10 with the SEC.
Aurora Cannabis (NASDAQ: ACB) has announced a strategic supply agreement with SNDL Inc., expanding their existing partnership. Under the new three-year agreement, valued at $27 million, SNDL will supply Aurora with premium cannabis flower products from their indoor facility in Atholville, New Brunswick.
The agreement includes an extension option and builds upon an existing supply relationship between the two companies for cannabis products and input material manufacturing. Aurora's CEO Miguel Martin emphasized the company's focus on maintaining a hybrid manufacturing network, following their strong third quarter performance driven by record-setting growth in international medical cannabis.
Aurora Cannabis (NASDAQ: ACB) reported strong fiscal Q3 2025 results with total net revenue of $88.2 million, up 37% YoY. The company achieved record-breaking performance across multiple metrics, including global medical cannabis net revenue of $68.1 million (up 51% YoY), net income of $31.2 million (up 282% YoY), and adjusted EBITDA of $23.1 million (up 316% YoY).
The company's international net revenue grew 112% and represented 60% of global medical cannabis revenue. The plant propagation segment increased 22% due to organic expansion. Aurora maintained a strong balance sheet with $180 million in cash and a debt-free cannabis business, except for $57.9 million in non-recourse debt related to Bevo Farms.
Medical cannabis contributed 77% of consolidated net revenue with a 74% adjusted gross margin. Consumer cannabis revenue decreased 15% to $9.9 million as the company prioritized its higher-margin medical cannabis business.
Aurora Cannabis (NASDAQ: ACB) has launched IndiMed, its first German-cultivated medical cannabis brand, manufactured at their EU-GMP facility in Leuna, Germany. This development follows Germany's recent cannabis decriminalization and positions Aurora as one of only three licensed cultivators in the country.
The initial product release is Island Sweet Skunk, a dried flower sativa variant containing 20% THC and <1% CBD, scheduled for availability on January 27. The product is cultivated under GACP and EU-GMP guidelines, featuring hand-harvested flowers that undergo controlled drying and laboratory testing for purity and potency.
As the world's largest medical cannabis company in legal markets, Aurora's expansion in Germany demonstrates its commitment to serving the country's growing patient base with locally produced, high-quality medical cannabis products.
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), a leading global medical cannabis company, has announced its upcoming third quarter 2025 financial results conference call. The event is scheduled for Wednesday, February 5, 2025, at 8:00 a.m. Eastern Time (6:00 a.m. Mountain Time). The company will release its financial results before markets open on the same day.
The conference call will be hosted by Miguel Martin, Executive Chairman and CEO, and Simona King, CFO, and will include a question and answer session. Investors can access the webcast through the company's investor relations website.
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB) has launched an internship program at its EU-GMP facility in Leuna, Germany, partnering with Erfurt University of Applied Sciences. The six-month program targets students from the Horticultural Crop Production course, offering hands-on experience in medical cannabis cultivation.
The program will cover all aspects of medical cannabis production, including cloning, care, harvesting, packaging, and cleaning, along with participation in research and development projects. The Leuna facility is among the few sites in Germany authorized to grow medical cannabis, featuring state-of-the-art indoor cultivation methods and sustainable practices.
According to Michael Simon, President of Aurora Europe (Interim), this initiative aims to provide students with unparalleled industry insights while collaborating with leading experts in the global medical cannabis sector.
Aurora Cannabis Inc. (NASDAQ: ACB) has announced a distribution partnership between MedReleaf Australia and The Entourage Effect to expand access to premium medical cannabis products in Australia. The Entourage Effect will serve as a wholesaler for MedReleaf Australia's portfolio, including CraftPlant, Aurora, and IndiMed brands.
The partnership aims to strengthen Aurora's distribution network in Australia through MedReleaf Australia, its wholly-owned subsidiary that meets TGA-GMP standards. This collaboration represents Aurora's commitment to expanding its presence in the growing Australian medical cannabis market while ensuring broader access to their medical cannabis portfolio.
Aurora Cannabis (NASDAQ: ACB) has announced new medical cannabis product developments from its research facility, Aurora Coast. The company introduced several innovations including: Aurora CBD Varius (1g, 510 Cartridge), MedReleaf Esprit De Corps (5g and 15g) with 20-29% THC, MedReleaf Sedamen (1g, 510 Cartridge), MedReleaf Noculus (5g and 15g) with 25-31% THC, and WMMC Seasonal Stash - Frosted Alpine (10g) with 24-30% THC. These products are available through AuroraMedical.com, demonstrating Aurora's commitment to providing patients with premium cannabis products.
Aurora Cannabis (NASDAQ: ACB) announces expansion of its recreational product portfolio with new offerings across Greybeard, San Rafael '71, and Tasty's brands. The new lineup includes Greybeard's Banana Gas Pure Live Resin Vape, Country Lemon Terp Slush, and Critical Diesel Pre-Rolls; San Rafael '71's 20 Pack Pre-Rolls; and Tasty's Diamond Infused Pre-Rolls in Mango, Honeydew, and Melon varieties, plus a Grape 510 Vape. These products focus on delivering premium, science-driven offerings with emphasis on flavor and intensity for Canadian cannabis consumers.
FAQ
What is the current stock price of Aurora Cannabis (ACB)?
What is the market cap of Aurora Cannabis (ACB)?
What is Aurora Cannabis Inc. primarily known for?
Where is Aurora Cannabis Inc. headquartered?
What are some of the brands under Aurora Cannabis?
What recent products has Aurora Cannabis launched?
What is Aurora's financial outlook for 2024?
What significant acquisitions has Aurora made recently?
What certifications do Aurora's production facilities hold?
How does Aurora contribute to the U.S. cannabis market?
What international operations does Aurora have?
How does Aurora ensure the quality of its products?
